<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02540265</url>
  </required_header>
  <id_info>
    <org_study_id>REC-15-014</org_study_id>
    <nct_id>NCT02540265</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery</brief_title>
  <official_title>A Phase 2, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety, Efficacy, and Pharmacokinetics of N1539 Following Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recro Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recro Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety of N1539 in subjects with acute
      moderate to severe pain following unilateral bunionectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events</measure>
    <time_frame>Through Day 30 Follow-up</time_frame>
    <description>Number of subjects reporting treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect Size of N1539 Doses Using the Summed Pain Intensity Difference Over the First 48 Hours (SPID48)</measure>
    <time_frame>48 Hours</time_frame>
    <description>Effect size was estimated based on SPID48 derived using 2-hour windowed last observation carried forward (W2LOCF) method and an analysis of covariance (ANCOVA) model that included treatment and baseline PI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summed Pain Intensity Difference Over the First 48 Hours (SPID48)</measure>
    <time_frame>48 Hours</time_frame>
    <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID was better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summed Pain Intensity Difference (SPID) at Other Intervals</measure>
    <time_frame>48 Hours</time_frame>
    <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID was better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Use of Rescue Medication (Oral Opioids)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Pain, Post-operative</condition>
  <arm_group>
    <arm_group_label>N1539 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N1539 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV Placebo every 24 hours for up to 3 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N1539</intervention_name>
    <arm_group_label>N1539 30mg</arm_group_label>
    <arm_group_label>N1539 60mg</arm_group_label>
    <other_name>Intravenous meloxicam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Placebo</intervention_name>
    <arm_group_label>IV Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily provide written informed consent.

          -  Male or female between 18 and 75 years of age, inclusive.

          -  Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair

          -  Be American Society of Anesthesiology (ASA) physical class 1 or 2.

          -  Female subject are eligible only if all the following apply:

               -  Not pregnant;

               -  Not lactating;

               -  Not planning to become pregnant during the study;

               -  Commit to the use of an acceptable form of birth control for the duration of the
                  study through Day 30.

          -  Have a body mass index ≤35 kg/m2

          -  Be able to understand the study procedures, comply with all study procedures, and
             agree to participate in the study program.

        Exclusion Criteria:

          -  Have a known allergy to meloxicam or any excipient of N1539, D5W, aspirin, other
             non-steroidal anti-inflammatory drugs (NSAIDs) or to any peri- or postoperative
             medications used in this study.

          -  Have a clinically significant abnormal clinical laboratory test value.

          -  Have history of or positive test results for HIV, or hepatitis B or C.

          -  Have a history or clinical manifestations of significant renal, hepatic,
             cardiovascular, metabolic, neurologic, psychiatric, or other condition that would
             preclude participation in the study.

          -  Have a history of migraine or frequent headaches, seizures, or are currently taking
             anticonvulsants.

          -  Have another painful physical condition that may confound the assessments of post
             operative pain.

          -  Have a history of syncope or other syncopal attacks.

          -  Have evidence of a clinically significant 12 lead ECG abnormality.

          -  Have a history of alcohol abuse (regularly drinks &gt; 4 units of alcohol per day; 8 oz.
             beer, 3 oz. wine, 1 oz. spirits) or prescription/illicit drug abuse..

          -  Have positive results on the urine drug screen or alcohol breath test indicative of
             illicit drug or alcohol abuse.

          -  Have been receiving or have received chronic opioid therapy defined as greater than 15
             morphine equivalents units per day for greater than 3 out of 7 days per week over a
             one-month period within 12 months.

          -  Use concurrent therapy that could interfere with the evaluation of efficacy or safety,
             such as any drugs which in the investigator's opinion may exert significant analgesic
             properties or act synergistically with N1539.

          -  Unable to discontinue medications, that have not been at a stable dose for at least 14
             days prior to the scheduled bunionectomy procedure, within 5 half lives of the
             specific prior medication (or, if half life is not known, within 48 hours) before
             dosing.

          -  Have utilized corticosteroids, either systemically, inhalational either intranasally
             or oral, or by intra-articular injection, within 14 days prior to the study.

          -  Have received any investigational product within 30 days before dosing with study
             medication.

          -  Be receiving warfarin, lithium, or a combination of furosemide with either an
             angiotensin converting enzyme inhibitor or an angiotensin receptor blocker

          -  Be currently receiving treatment with oral meloxicam (Mobic®)

          -  Have previously received N1539 in clinical trials, or had bunionectomy in the last 3
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chesapeake Research Group, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2015</study_first_posted>
  <results_first_submitted>January 16, 2017</results_first_submitted>
  <results_first_submitted_qc>May 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bunion</keyword>
  <keyword>Bunionectomy</keyword>
  <keyword>Pain</keyword>
  <keyword>Analgesia</keyword>
  <keyword>N1539</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>N1539 30mg</title>
          <description>N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
N1539</description>
        </group>
        <group group_id="P2">
          <title>N1539 60mg</title>
          <description>N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
N1539</description>
        </group>
        <group group_id="P3">
          <title>IV Placebo</title>
          <description>IV Placebo every 24 hours for up to 3 doses.
Intravenous Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Completion</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population includes all subjects randomized to treatment</population>
      <group_list>
        <group group_id="B1">
          <title>N1539 30mg</title>
          <description>N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
N1539</description>
        </group>
        <group group_id="B2">
          <title>N1539 60mg</title>
          <description>N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
N1539</description>
        </group>
        <group group_id="B3">
          <title>IV Placebo</title>
          <description>IV Placebo every 24 hours for up to 3 doses.
Intravenous Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.6" spread="12.66"/>
                    <measurement group_id="B2" value="44.9" spread="16.67"/>
                    <measurement group_id="B3" value="49.2" spread="12.81"/>
                    <measurement group_id="B4" value="47.2" spread="14.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Pain Intensity (0-10 NPRS)</title>
          <description>Pain intensity was recorded using a Numeric Pain Rating Scale (NPRS; Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="2.00"/>
                    <measurement group_id="B2" value="7.4" spread="1.90"/>
                    <measurement group_id="B3" value="7.7" spread="2.24"/>
                    <measurement group_id="B4" value="7.6" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events</title>
        <description>Number of subjects reporting treatment emergent adverse events</description>
        <time_frame>Through Day 30 Follow-up</time_frame>
        <population>All subjects treated with ≥1 dose of study medication (Safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>N1539 30mg</title>
            <description>N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
N1539</description>
          </group>
          <group group_id="O2">
            <title>N1539 60mg</title>
            <description>N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
N1539</description>
          </group>
          <group group_id="O3">
            <title>IV Placebo</title>
            <description>IV Placebo every 24 hours for up to 3 doses.
Intravenous Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events</title>
          <description>Number of subjects reporting treatment emergent adverse events</description>
          <population>All subjects treated with ≥1 dose of study medication (Safety analysis set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect Size of N1539 Doses Using the Summed Pain Intensity Difference Over the First 48 Hours (SPID48)</title>
        <description>Effect size was estimated based on SPID48 derived using 2-hour windowed last observation carried forward (W2LOCF) method and an analysis of covariance (ANCOVA) model that included treatment and baseline PI score.</description>
        <time_frame>48 Hours</time_frame>
        <population>All subjects treated with ≥1 dose of study medication and who had baseline PI and at least one post baseline PI (mITT analysis set; efficacy analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>N1539 30mg</title>
            <description>N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
N1539</description>
          </group>
          <group group_id="O2">
            <title>N1539 60mg</title>
            <description>N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
N1539</description>
          </group>
          <group group_id="O3">
            <title>IV Placebo</title>
            <description>IV Placebo every 24 hours for up to 3 doses.
Intravenous Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Size of N1539 Doses Using the Summed Pain Intensity Difference Over the First 48 Hours (SPID48)</title>
          <description>Effect size was estimated based on SPID48 derived using 2-hour windowed last observation carried forward (W2LOCF) method and an analysis of covariance (ANCOVA) model that included treatment and baseline PI score.</description>
          <population>All subjects treated with ≥1 dose of study medication and who had baseline PI and at least one post baseline PI (mITT analysis set; efficacy analysis set)</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9241.9" spread="1411.74"/>
                    <measurement group_id="O2" value="-8350.6" spread="1413.30"/>
                    <measurement group_id="O3" value="-1991.3" spread="1448.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Effect Size</param_type>
            <param_value>1.01</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Effect Size</param_type>
            <param_value>0.87</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summed Pain Intensity Difference Over the First 48 Hours (SPID48)</title>
        <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID was better.</description>
        <time_frame>48 Hours</time_frame>
        <population>mITT analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>N1539 30mg</title>
            <description>N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
N1539</description>
          </group>
          <group group_id="O2">
            <title>N1539 60mg</title>
            <description>N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
N1539</description>
          </group>
          <group group_id="O3">
            <title>IV Placebo</title>
            <description>IV Placebo every 24 hours for up to 3 doses.
Intravenous Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Summed Pain Intensity Difference Over the First 48 Hours (SPID48)</title>
          <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID was better.</description>
          <population>mITT analysis set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9241.9" spread="1411.74"/>
                    <measurement group_id="O2" value="-8350.6" spread="1413.30"/>
                    <measurement group_id="O3" value="-1991.3" spread="1448.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0049</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0076</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summed Pain Intensity Difference (SPID) at Other Intervals</title>
        <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID was better.</description>
        <time_frame>48 Hours</time_frame>
        <population>mITT analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>N1539 30mg</title>
            <description>N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
N1539</description>
          </group>
          <group group_id="O2">
            <title>N1539 60mg</title>
            <description>N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
N1539</description>
          </group>
          <group group_id="O3">
            <title>IV Placebo</title>
            <description>IV Placebo every 24 hours for up to 3 doses.
Intravenous Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Summed Pain Intensity Difference (SPID) at Other Intervals</title>
          <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID was better.</description>
          <population>mITT analysis set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SPID6 (Hour 0-6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-793.87" spread="172.45"/>
                    <measurement group_id="O2" value="-663.17" spread="172.64"/>
                    <measurement group_id="O3" value="146.22" spread="176.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID12 (Hour 0-12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1655.1" spread="338.78"/>
                    <measurement group_id="O2" value="-1334.9" spread="339.15"/>
                    <measurement group_id="O3" value="319.67" spread="347.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID24 (Hour 0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3024.0" spread="644.63"/>
                    <measurement group_id="O2" value="-2793.3" spread="645.34"/>
                    <measurement group_id="O3" value="276.46" spread="661.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID12-24 (Hour 12-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1368.9" spread="343.34"/>
                    <measurement group_id="O2" value="-1458.4" spread="343.72"/>
                    <measurement group_id="O3" value="-43.21" spread="352.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID12-48 (Hour 12-48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7586.8" spread="1121.12"/>
                    <measurement group_id="O2" value="-7015.7" spread="1122.35"/>
                    <measurement group_id="O3" value="-2311.0" spread="1150.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID24-48 (Hour 24-48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6217.9" spread="817.22"/>
                    <measurement group_id="O2" value="-5557.3" spread="818.12"/>
                    <measurement group_id="O3" value="-2267.8" spread="838.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Applies to SPID 0-6, SPID 0-12, SPID 0-24, SPID 12-24, SPID 12-48, and SPID 24-48</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Applies to SPID 0-6, SPID 0-12, SPID 0-24, SPID 12-24, SPID 12-48, and SPID 24-48</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Use of Rescue Medication (Oral Opioids)</title>
        <time_frame>48 hours</time_frame>
        <population>mITT analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>N1539 30mg</title>
            <description>N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
N1539</description>
          </group>
          <group group_id="O2">
            <title>N1539 60mg</title>
            <description>N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
N1539</description>
          </group>
          <group group_id="O3">
            <title>IV Placebo</title>
            <description>IV Placebo every 24 hours for up to 3 doses.
Intravenous Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Use of Rescue Medication (Oral Opioids)</title>
          <population>mITT analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 0-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>N1539 30mg</title>
          <description>N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
N1539</description>
        </group>
        <group group_id="E2">
          <title>N1539 60mg</title>
          <description>N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
N1539</description>
        </group>
        <group group_id="E3">
          <title>IV Placebo</title>
          <description>IV Placebo every 24 hours for up to 3 doses.
Intravenous Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Randall Mack</name_or_title>
      <organization>Recro Pharma, Inc.</organization>
      <phone>484-395-2470 ext 2406</phone>
      <email>rmack@recropharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

